[go: up one dir, main page]

WO2017147420A1 - Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires - Google Patents

Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires Download PDF

Info

Publication number
WO2017147420A1
WO2017147420A1 PCT/US2017/019351 US2017019351W WO2017147420A1 WO 2017147420 A1 WO2017147420 A1 WO 2017147420A1 US 2017019351 W US2017019351 W US 2017019351W WO 2017147420 A1 WO2017147420 A1 WO 2017147420A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
host
compound
cftr
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/019351
Other languages
English (en)
Inventor
Gill Diamond
Kristina DIFRANCO
Scott H. RANDELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
University of Florida Research Foundation Inc
Original Assignee
University of North Carolina at Chapel Hill
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of Florida Research Foundation Inc filed Critical University of North Carolina at Chapel Hill
Publication of WO2017147420A1 publication Critical patent/WO2017147420A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • Cystic Fibrosis is a genetic disorder that affects the body's production of mucus, sweat, and digestive fluids, leading to complications in the respiratory system, digestive system, and other organs. While CF is a life limiting disease, due to better treatment options, people with CF are living longer, more productive lives than they did in the past. CF arises from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride ion channel. CFTR is expressed in many organs, including the lungs, pancreas, salivary glands, kidneys, liver, sweat glands, and reproductive tract.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • CFTR protein encoded by the mutated CFTR gene may be functional but, due to misfolding or other problem, cannot make it to the cell membrane, which leads to disease symptoms.
  • Improper chloride transport from defective CFTR leads to thickened mucous secretions, persistent bacterial infections, lung tissue damage and malnutrition due to poor vitamin absorption.
  • the lungs are the organ most commonly studied in CF because of the severity of the effects at that site.
  • the thickened mucus in the lungs provides an environment favorable for microbial growth.
  • the most common bacterial species found in CF is
  • Vitamin D is a principal factor that maintains calcium homeostasis and is required for bone development and maintenance. Vitamin D deficiency during bone development causes rickets.
  • Adult vitamin D deficiency which is common in the elderly population, can cause secondary hyperparathyroidism that can result in osteomalacia and increased risk of fracture.
  • Vitamin D deficiency is also common among patients with CF, with as much as 60% having serum vitamin D levels below 30ng/ml (75nM), even with supplementation. This deficiency, which may result from malabsorption of the fat-soluble nutrient, as well as other potential causes, can lead to low bone mass, osteoporosis, and fractures in CF patients.
  • vitamin D deficiency has been associated with increased pulmonary exacerbations, increased bacterial infection, and inflammation in CF patients.
  • Vitamin D is currently recommended as a dietary supplement for all patients with osteoporosis or decreased bone mass and has been reported to prevent bone loss and decrease fracture incidence for both healthy individuals and CF patients. Recent evidence has indicated an interrelationship between vitamin D and health beyond just bone, including effects on preventing or at least partially protecting against certain autoimmune diseases such as diabetes and multiple sclerosis, and inhibition of proliferation of a number of malignant cells such as breast and prostate cancer cells. Furthermore, vitamin D deficiency has been associated with increased susceptibility to respiratory infections.
  • the present disclosure provides methods for topically administering vitamin D compounds to the respiratory tissues of a host, methods for treating cystic fibrosis and other respiratory disorders in a host, methods of increasing the amount of membrane localized cystic fibrosis conductance regulator (CFTR) in a host, methods of decreasing epithelial sodium channel (ENaC) activity in respiratory tissue epithelial cells in a host, and compositions including an aerosol formulation comprising a vitamin D compound in the form of cholecalciferol (D 3 ).
  • CFTR membrane localized cystic fibrosis conductance regulator
  • ENaC epithelial sodium channel
  • Embodiments of methods of the present disclosure include topically administering to the respiratory tissue of a host with cystic fibrosis an effective amount of a composition comprising a vitamin D compound, where the vitamin D compound is effective to increase the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory tissue epithelial cells in the host.
  • the present disclosure also describes methods of treatment for cystic fibrosis, the method including topically administering to the respiratory tissues of a host in need of treatment for cystic fibrosis an effective amount of a composition comprising a vitamin D compound in the form of cholecalciferol (D 3 ) and a pharmaceutically acceptable carrier, where the vitamin D compound is effective to alleviate at least one respiratory symptom of the host.
  • Embodiments of the present disclosure also include methods of treatment for cystic fibrosis, the methods including treating cystic fibrosis by topically administering to the respiratory tissues of a host in need of treatment for cystic fibrosis an effective amount of a composition comprising a vitamin D compound, where the vitamin D compound is effective to increase the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory tissue epithelial cells of the host and is effective to alleviate at least one respiratory symptom of the host.
  • CFTR membrane localized cystic fibrosis conductance regulator
  • Methods of the present disclosure further include decreasing epithelial sodium channel (ENaC) activity in respiratory tissue epithelial cells in a host with cystic fibrosis by topically administering to the respiratory tissue of the host an effective amount of a composition comprising a vitamin D compound, wherein the vitamin D compound is effective to decrease the ENaC activity in the respiratory tissue epithelial cells in the host.
  • ENaC epithelial sodium channel
  • Methods of the present disclosure also include methods of increasing the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory tissue epithelial cells, the methods including topically administering directly to the respiratory tissue of a host an effective amount of a composition comprising a vitamin D compound in the form of cholecalciferol (D 3 ), where the vitamin D compound is converted to 25-hydroxyvitamin D 3 (250HD 3 ) by the host epithelial cells, where the 250HD 3 is converted to 1 ,25- dihydroxy vitamin D 3 (1 ,25(OH) 2 D 3 ) by the host.
  • CFTR membrane localized cystic fibrosis conductance regulator
  • Embodiments of the present disclosure also include methods of treating a respiratory condition in a host, the methods including topically administering to the respiratory tissue of the host an effective amount of a composition comprising a vitamin D compound, where the vitamin D compound is effective to increase the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory tissue epithelial cells of the host, decrease epithelial sodium channel (ENaC) activity in the respiratory tissue epithelial cells of the host, or both.
  • CFTR membrane localized cystic fibrosis conductance regulator
  • ENaC epithelial sodium channel
  • compositions including an aerosol formulation comprising a vitamin D compound in the form of cholecalciferol (D 3 ) and a pharmaceutically acceptable carrier, where the composition is adapted for aerosol delivery by a nebulizer, personal inhaler, or other respiratory airway delivery device.
  • FIG. 1 is a bar graph illustrating the induction of CFTR mRNA in cultured human bronchial epithelial (HBE) cells by administration of 1 ,25(OH) 2 D 3 .
  • Cultures of primary normal human bronchial epithelial cells (NHBE), or growth enhanced HBE cell lines (BEAS-2B, UNC-CF 1 T), or well-differentiated NHBE cultures from a non-CF donor or CF donor (all in triplicate) were treated with either ethanol control, or 10nM 1 ,25(OH) 2 D 3 for 6 hours.
  • Total mRNA was isolated and CFTR was quantified by quantitative RT-PCR relative to ⁇ 2- microglobulin. Data are shown as mean +/- SEM .
  • FIG. 2 illustrates induction of CFTR protein in UNC-CF1 T cells after treatment with 10nM 1 ,25(OH) 2 D 3 or 0.1 % ethanol vehicle only for 24 hours and shows flow cytometry of permeabilized cells stained with an anti-CFTR antibody followed by a fluorescent secondary antibody (from I to r, first peak: unstained cells; second peak: ethanol; third peak:
  • FIG. 3 is a series of digital images illustrating fluorescent microscopy of cells grown on coverslips, treated with the ethanol vehicle only or 1 ,25(OH) 2 D 3 .
  • FIGS. 4A-C illustrate activation of vitamin D in airway epithelial cells.
  • FIG . 4A illustrates total mRNA isolated from cultured BEC from a non-CF donor and a CF patient and subjected to RT-PCR using primers specific for CYP27B1 , CYP27A1 and CYP2R1 .
  • FIG . 4B illustrates protein expression by BEAS2B and HEK293 ells lysed and subjected to western blot analysis using antibodies to the hydroxylases, with ⁇ -actin as a loading control.
  • FIG. 4C is a set of bar graphs illustrating conversion of Vitamin D 3 to 250HD 3 . BECs obtained from three healthy patients (top) and three CF patients (bottom) were treated with indicated doses of vitamin D 3 or vehicle control for 24 hours, after which time 250HD 3 levels were measured in supernatant. *p ⁇ 0.05 vs. control.
  • FIGS 5A-5B are bar graphs illustrating activation of vitamin D in HBE cells.
  • FIG . 5A shows induction of Cyp24A1 mRNA expression in 3 cell types (NHBE, UNC-N3T, and Beas- 2B) after treatment with the inactive parent vitamin D at 6 and 24 hours vs. ethanol control only.
  • FIG. 5B shows expression of CFTR (as well as CYP24A1 mRNA levels) in apically stimulated (submerged or apical surface vitamin D exposure) cultures (FIG . 5B) .
  • FIG. 6 is a bar graph illustrating vitamin D-mediated regulation of Keratin 18 and Aha1 . Data are shown as mean +/- SEM . Differences compared to control are significant in both cases at p ⁇ 0.00001 .
  • FIG. 7 is a bar graph illustrating induction of Cyp24A1 and CFTR gene expression in mouse tracheas after intranasal administration.
  • Figures 8A-8B are bar graphs illustrating the induction of gene expression in the tracheas of mice by intranasally delivered vitamin D (as inactive vitamin D 3 , or as
  • FIG. 8A shows induction as a function of CYP224A1 mRNA levels
  • FIG. 8B shows relative CFTR mRNA levels.
  • FIG. 9 is bar graph illustrating the effect of vitamin D treatment (administered via injection) on mice in vivo. Data are shown as mean +/- SEM . The increase in CYP24A1 mRNA was significant at al days relative to control, p ⁇ 0.05.
  • FIGS. 10A-10B illustrate the effect of vitamin D on ion transport.
  • FIG. 10A illustrates an Ussing chamber analysis of one non-CF donor sample, treated with ethanol vehicle alone, or with 1 ,25(OH) 2 D 3 in triplicate. It illustrates a tracing of short circuit current across the epithelial cells as a function of time, with vertical arrows indicating when the indicated chemicals were added to the Ussing chamber.
  • FIG . 10B is a bar graph illustrating the mean relative ENaC activity (measured as function of amiloride sensitive short circuit current) in triplicate wells from 18 different (CF and non-CF) donors.
  • Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of biology, medicine, biochemistry, molecular biology, pharmacology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
  • compositions like those disclosed herein, but which may contain additional structural groups, composition components or method steps (or analogs or derivatives thereof as discussed above). Such additional structural groups, composition components or method steps, etc. , however, do not materially affect the basic and novel characteristic(s) of the compositions or methods, compared to those of the corresponding compositions or methods disclosed herein.
  • Consisting essentially of or “consists essentially” or the like when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
  • Vitamin D compound includes any compound being vitamin D or an analogue or metabolite thereof that is capable of treating pulmonary symptoms of cystic fibrosis.
  • Vitamin D compounds include, but are not limited to, vitamins D2 (ergocalciferol) and D3 (cholecalciferol) (sometimes collectively referred to as “calciferol”) ; compounds and isomers and derivatives of these compounds, such as vitamin D2 and D3 prohormones (e.g. , 25-hydroxyvitamin D 2 (250HD 2 ) and 25-hydroxyvitamin D 3 (250HD 3 ), collectively “calcidiol”); active vitamin D2 and D3 (e.g.
  • Vitamin D compounds may also include less common vitamin D compounds such as vitamin D1 compounds, vitamin D2 compounds, vitamin D4 compounds, and the like, as well as synthetic versions of the above mentioned Vitamin D compounds.
  • active vitamin D compounds are vitamin D compounds that are ligands for the vitamin D receptor (VDR ligands).
  • active vitamin D 3 refers to 1 ,25-dihydroxyvitamin D 3
  • inactive vitamin D 3 refers to cholecalciferol
  • intermediate vitamin D 3 refers to 25-hydroxyvitamin D 3 (250HD 3 )
  • vitamin D 2 inactive, intermediate, and active forms refers to 25-hydroxyvitamin D 3 (250HD 3 ), with similar references for the vitamin D 2 inactive, intermediate, and active forms.
  • the term "aerosol,” “aerosol formulation,” or “aerosolized” composition refers to a suspension of solid or liquid particles in a gas.
  • aerosol may be used generally to refer to a compound (e.g., a vitamin D compound) that has been vaporized, nebulized, or otherwise converted from a solid or liquid form to an inhalable form including suspended solid or liquid drug particles.
  • An aerosol may include other compounds in addition to the active compound. The other compounds may also be solid, liquid, or gas an in inhalable form.
  • respiratory system refers to the system of organs in the body responsible for the intake of oxygen and the expiration of carbon dioxide.
  • the system generally includes all the air passages from the nose to the pulmonary alveoli. In mammals it is generally considered to include the lungs, bronchi, bronchioles, trachea, nasal passages, and diaphragm.
  • delivery of a compound to the "respiratory system” indicates that a drug is delivered to one or more of the air passages of the respiratory system, in particular to the lungs.
  • respiratory disorder refers to a condition of the respiratory system of a host in which the respiratory function of the host is less than normal/typical for a host of the same age, gender, etc.
  • such disorder may include symptoms such as, but not limited to, shortness of breath, inadequate blood oxygen levels, improper functioning of the lungs, airways, etc., excessive mucus production, labored breathing, and the like.
  • Example respiratory disorders include, but are not limited to, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and the like.
  • the term "formulation” generally refers to any mixture, solution, suspension, or the like, which contains an active ingredient and a carrier and has physical properties such that when the formulation is moved through an inhaler or respirator device as described herein, the formulation is in a form that is delivered/inhaled/blown by positive pressure into the lungs of a patient.
  • the active ingredient may be a vitamin D compound (as defined above).
  • the carrier may be any pharmaceutically acceptable flowable agent that is compatible for delivery with the active agent.
  • the formulation may also include, but are not limited to, other active agents/drugs, such as but not limited to, pulmonary surfactants.
  • Useful drugs include agents defined in this document, systemically-active drugs delivered to the airways, and useful diagnostics including those used in connection with ventilation imaging.
  • Formulations may be, for example, solutions, e.g., aqueous solutions, ethanoic solutions, aqueous/ethanoic solutions, saline solutions, colloidal suspensions and microcrystalline suspensions.
  • formulations can be solutions or suspensions of compounds in a low boiling point propellant.
  • the formulations can be in solid form.
  • Solid form preparations include powders, tablets, dispersible granules, and capsules. Solid form preparations will be vaporized or aerosolized by an appropriate inhaler and/or respirator device, so as to be inhaled by a host or patient.
  • Pharmaceutically acceptable excipients can be volatile or nonvolatile.
  • Volatile excipients when heated, are concurrently volatilized, aerosolized, and inhaled with the active agent.
  • Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid, and solid solvents.
  • vitamin D compounds and formulations of the present disclosure may be referenced as being delivered by inhalation or utilized by the respiratory or pulmonary system, it will be appreciated that such delivery includes not only oral inhalation or intratracheal administration, but also administration to nasal passageways and nasal membranes, which is also within the scope of this present disclosure.
  • the drugs and formulations discussed here are subject to delivery by inhalation via an oral or nasal route as well as other methods of administration topically to the respiratory tissues of a host.
  • polypeptide and protein refer to a polymer of amino acids of three or more amino acids in a serial array, linked through peptide bonds.
  • polypeptide includes proteins, protein fragments, protein analogues, oligopeptides, and the like.
  • polypeptides contemplates polypeptides as defined above that are encoded by nucleic acids, produced through recombinant technology (isolated from an appropriate source such as a bird), or synthesized.
  • polypeptides further contemplates polypeptides as defined above that include chemically modified amino acids or amino acids covalently or non-covalently linked to labeling ligands.
  • polynucleotide oligonucleotide
  • nucleic acid sequence include, but are not limited to, coding sequences
  • control sequences e.g. , translational start and stop codons, promoter sequences, ribosome binding sites, polyadenylation signals, transcription factor binding sites, transcription termination sequences, upstream and downstream regulatory domains, enhancers, silencers, and the like
  • regulatory sequences DNA sequences to which a transcription factor(s) binds and alters the activity of a gene's promoter either positively (induction) or negatively (repression)
  • RNA typically refers to a hereditary unit corresponding to a sequence of DNA that occupies a specific location on a chromosome and that contains the genetic instruction for a characteristic(s) or trait(s) in an organism.
  • gene product refers to RNAs or proteins that are encoded by the gene.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization (e.g. , not worsening) of disease, delaying or slowing of disease progression, substantially preventing spread of disease, amelioration or palliation of the disease state, and remission (partial or total) whether detectable or undetectable.
  • stabilization e.g. , not worsening
  • substantially preventing spread of disease amelioration or palliation of the disease state
  • remission partial or total
  • “treat”, “treating”, and “treatment” can also be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • the terms “prevent,” “prophylactically treat,” or “prophylactically treating” refer to completely, substantially, or partially preventing a disease/condition or one or more symptoms thereof in a host.
  • preventing or “prophylactic treatment” can include preventing the development and appearance of new symptoms of cystic fibrosis in a host.
  • host refers to any living entity in need of treatment, including humans, mammals (e.g. , cats, dogs, horses, mice, rats, pigs, hogs, cows, and other cattle), birds (e.g. , chickens), and other living species that are in need of treatment.
  • the term “host” includes humans.
  • the term “human host” or “human subject” is generally used to refer to human hosts.
  • the term "host” typically refers to a human host, so when used alone in the present disclosure, the word “host” refers to a human host unless the context clearly indicates the intent to indicate a non-human host.
  • Hosts that are "predisposed to" condition(s) can be defined as hosts that do not exhibit overt symptoms of one or more of these conditions but that are genetically, physiologically, or otherwise at risk of developing one or more of these conditions.
  • expression describes the process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation. Expression generally refers to the "expression” of a nucleic acid to produce a polypeptide, but it is also generally acceptable to refer to "expression" of a polypeptide, indicating that the polypeptide is being produced via expression of the corresponding nucleic acid.
  • upregulate refers to the act of increasing the expression and/or activity of a protein or other gene product relative to the expected or average expression or activity of the protein in a corresponding cell or organism (e.g., upregulation of CFTR or Krt18 in a respiratory tissue cell of a CF patient means increasing expression or activity of the protein relative to what is expected in a typical, untreated, respiratory tissue cell of a CF patient).
  • downregulation refers to decreasing the expression and/or activity of a protein or other gene product relative to the expected or average expression or activity of the protein in a corresponding cell or organism, (e.g., downregulation of Aha1 in a respiratory tissue cell of a CF patient means decreasing expression or activity of the protein relative to what is expected in a typical, untreated, respiratory tissue cell of a CF patient).
  • increase can refer to the activity, function, or amount of a protein or gene product relative to an unmodified, untreated, expected, or average (e.g., a control) in a corresponding cell or organism. For instance, “increasing the amount” of membrane localized CFTR in a cell, tissue, or host organism indicates that the cell or host in question has a greater amount of membrane localized CFTR than in a corresponding cell, tissue, or host organism that has not been treated. Similarly, “decrease” can refer to the activity, function, or amount of a protein or gene product relative to an unmodified, untreated, expected, or average (e.g., a control) in a corresponding cell or organism. For instance, “decreasing the activity" of a protein in a cell, tissue, or host organism indicates that the cell or host in question has a lower activity of the protein than a corresponding untreated or unmodified cell or organism.
  • administration is meant introducing a compound of the present disclosure into a subject; it may also refer to the act of providing a composition of the present disclosure to a subject (e.g., by prescribing).
  • the preferred route of administration of the compositions of the present disclosure is endotracheal administration or other administration directly to the respiratory system of a host.
  • direct administration to the respiratory tissues of a host is meant that the composition (e.g., a composition including a vitamin D compound of the present disclosure) is directly administered or applied to these tissues as opposed to a systemic delivery where the compound must first be metabolized by the host system.
  • An embodiment of direct administration would be topical administration to the tissues of interest, (e.g. respiratory epithelial tissues), such as by inhalation or other intra-tracheal
  • an effective amount refers to a sufficient amount of the vitamin D compound to achieve the desired result (e.g., increasing the amount of membrane localized CFTR, treating/alleviating respiratory symptoms of CF, etc.) at a reasonable benefit/risk ratio applicable to any medical treatment.
  • respiratory airway delivery device refers to an inhaler, nebulizer, respirator, or other type of device that is designed/configured to allow delivery of a composition (e.g., in an aerosol formulation or other formulation appropriate for delivery via respiration) via the airways (e.g., oral, nasal, tracheal) of a patient to provide direct (e.g., topical) delivery of the formulation to all or portions of the respiratory tissues of a patient.
  • a composition e.g., in an aerosol formulation or other formulation appropriate for delivery via respiration
  • the airways e.g., oral, nasal, tracheal
  • Consisting essentially of or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
  • the embodiments of the present disclosure encompass compositions and methods of treating cystic fibrosis (CF) and/or other respiratory disorders.
  • Embodiments of the present disclosure also include methods of altering ion transport physiology at the epithelial cell surface, by increasing the amount of membrane localized cystic fibrosis conductance regulator (CFTR) and/or by reducing the amount of epithelial sodium channel (ENaC) activity in a patient with CF. In embodiments, these methods are accomplished by direct administration of vitamin D compounds to the respiratory tissues of the patient, and the like.
  • inactive vitamin D compounds e.g., calciferol, etc.
  • the active form e.g., calcitriol
  • the present disclosure demonstrates that, when delivered directly to respiratory tissue cells of patients with CF, the vitamin D compound(s) is effective to increase the level of CFTR on the membrane of cells and/or to decrease ENaC activity, which helps ameliorate the physiological defect in CF.
  • vitamin D3, 1 ,25-dihydroxyvitamin D3 (1 ,25(OH) 2 D 3 )
  • the hormonally active form of vitamin D3, 1 ,25-dihydroxyvitamin D3 (1 ,25(OH) 2 D 3 )
  • is produced by two sequential hydroxylations of vitamin D It has been generally accepted that this occurs initially by one of a number of 25-hydroxylases in the liver (leading to 25- hydroxyvitamin D 3 , or 250HD 3 ) , and then by 25-hydroxyvitamin Dl a-hydroxylase (1 a- (OH)ase) in the kidney [1 , 2].
  • 25-hydroxylases are reported to convert vitamin D 3 to 250HD 3 , with the best-studied being Cyp27A1 and Cyp2R1 [3, 4].
  • the actions of 1 ,25(OH) 2 D 3 are mediated, similar to other steroid hormones, by a nuclear receptor (vitamin D receptor, VDR) which heterodimerizes with the retinoid X receptor and interacts with a specific DNA sequence (the vitamin D response element (VDRE)) in target genes and modulates their transcription [7, 8].
  • VDR nuclear receptor
  • VDRE vitamin D response element
  • VDR/1 ,25(OH) 2 D 3 transcription complex can take several hours to result in an observable change in cellular activities
  • 1 ,25(OH) 2 D 3 has also been reported to rapidly affect intracellular processes by binding membrane VDR or 1 ,25D 3 -membrane-associated, rapid response steroid-binding protein (1 ,25D 3 -MARRS) receptor to turn on a number of kinases, such as protein kinases A and C [9- 1 1 ].
  • the mechanisms involved in VDR mediated transcription are now being defined. It is possible that cell and promoter-specific functions of VDR may be mediated through differential recruitment of co-activators, and that cooperation between VDR and VDR co-activators may be a mechanism that couples extracellular signals to vitamin D action.
  • vitamin D is important for calcium homeostasis [1 ]
  • vitamin D is important for calcium homeostasis [1 ]
  • vitamin D has numerous other functions including immunomodulatory effects [12].
  • therapeutic appeal of vitamin D lies in its antimicrobial and anti-inflammatory properties.
  • Vitamin D downregulates the expression of inflammatory cytokines IL-6 and IL-8, which have been reported to be upregulated in CF patients [13, 14]. These anti-inflammatory properties could prevent recruitment of neutrophils, which contribute to the lung tissue damage.
  • vitamin D is very safe, even at high doses, and easily absorbed and stored.
  • this absorption is often reduced, leading to a chronic hypovitaminosis D, which cannot easily be remedied by systemic supplementation.
  • serum 250HD 3 levels will only rise to a specific level, due to the feedback mechanism, based on the induction of the vitamin D-inactivating enzyme 24-hydroxylase, encoded by the CYP24A1 gene.
  • 1 ,25(OH) 2 D 3 enhances our understanding of how 1 ,25(OH) 2 D 3 affects CF, and provides a novel therapeutic agent for treatment, possibly as an adjunctive therapy together with other CFTR modulators.
  • modulators include correctors, such as VX-809, which corrects the folding and processing defect of the DF508 mutation [22], and potentiators such as VX-770, which increase the flow of ions through CFTR that is already at the surface, as observed in patients with the G551 D mutation [23].
  • Topical application of vitamin D is a newly developed therapy that is currently only used on the skin to treat certain dermatological conditions, as a safe and effective mechanism for the introduction of high concentrations of vitamin D and its metabolites to a specific location.
  • the methods of the present disclosure are believed to be the first demonstration of introduction of vitamin D directly to the respiratory system of a host (e.g. topical application to respiratory tissues, e.g. , tracheal, bronchial, and lung tissues, via airways) in order to circumvent the issues related to CF malabsorption of vitamin D, the systemic regulation of 250HD 3 levels, to increase CFTR mRNA and protein levels and/or to decrease activity of the epithelial sodium channel (ENaC).
  • a host e.g. topical application to respiratory tissues, e.g. , tracheal, bronchial, and lung tissues, via airways
  • the present disclosure demonstrates that the inactive form of vitamin D (cholecalciferol) is activated by the airway epithelial cells to the active form and that topical treatment of air-liquid interface cultured HBE cells with cholecalciferol also leads to induction of CFTR.
  • the data show that this occurs in two cultured cell lines, as well as in well- differentiated, polarized primary HBE cell cultures from CF patients and non-CF donors and that induction is accompanied by an increase in protein levels on the surface of these cells.
  • inactive form of vitamin D can be administered therapeutically via the airways to the respiratory tissues of a CF patient, where it will be converted to the active form of vitamin D to increase levels of CFTR mRNA in the cytoplasm as well as on the surface of the airway epithelium.
  • This provides a safe and inexpensive therapy or adjunctive therapy to increase CFTR mRNA and protein levels to enhance the activity of CFTR correctors and potentiators to treat patients with CF.
  • Methods of the present disclosure thus include, among others, methods of using vitamin D compounds for treatment of CF and methods of increasing the amount of membrane localized cystic fibrosis conductance regulator (CFTR) in a patient with CF.
  • the vitamin D compounds of the present disclosure when delivered directly to the respiratory tissues of a host, are effective to treat symptoms of CF in the host by mediating the level of certain proteins in the host.
  • the vitamin D compounds are effective to increase the amount of membrane localized CFTR in a CF patient, which helps to control respiratory symptoms.
  • the vitamin D compounds are effective to decrease the amount of ENaC activity present in airway epithelial cells in a CF patient, which helps to control respiratory symptoms.
  • the vitamin D compounds when delivered directly to the respiratory tissues of a host with CF, are effective to increase membrane localized CFTR by upregulating or downregulating other proteins (e.g., Keratin 18 (Krt18), Keratin 8 (Krt8), Activator of Hsp90 ATPase-1 (Aha1), etc.) that are involved in the mediation of CFTR production and maintenance in epithelial tissue cells.
  • other proteins e.g., Keratin 18 (Krt18), Keratin 8 (Krt8), Activator of Hsp90 ATPase-1 (Aha1), etc.
  • methods of the present disclosure for treatment of cystic fibrosis include treating CF by administering directly to the respiratory tissues of a host in need of treatment for CF an effective amount of a composition comprising a vitamin D compound such that the vitamin D compound is effective to alleviate at least one respiratory symptom of the host.
  • delivering the vitamin D compound or a pharmaceutical composition including the compound directly to the respiratory tissue of a host includes topically administering the vitamin D compound to the respiratory tissues of the host, including tissues such as, but not limited to, lung tissues and other airway epithelial tissues (e.g., alveoli, bronchioles, bronchial epithelial tissues, tracheal epithelial tissues, nasal epithelial tissues, etc.).
  • topical administration to the respiratory tissues of a host is accomplished by administering the vitamin D compound via the airways of the host (such as oral or nasal inhalation, endotracheal administration, and the like).
  • airways of the host such as oral or nasal inhalation, endotracheal administration, and the like.
  • methods for airway delivery of compounds to the respiratory tissues of a host include, but are not limited to, inhalation (e.g. with the use of inhaler, nasal spray, nebulizer or other similar device), or, in if the patient is sedated or otherwise unconscious, the compound can be delivered endotracheal ⁇ (e.g., via an intubation tube or respirator).
  • the composition comprising the vitamin D compound may be in the form of an aerosol formulation, or other inhalable formulation (e.g., powder, fine mist, etc.).
  • the aerosol formulations can be made according to methods known to those of skill in the art.
  • the composition may also include a pharmaceutically acceptable carrier as well as other inactive and active compounds for treatment of symptoms of CF or other respiratory conditions, such as surfactants, other active agents used in the treatment of respiratory symptoms of CF, etc.
  • the method may include delivery of a composition consisting essentially of a vitamin D compound and a pharmaceutically acceptable carrier.
  • the aerosol or other inhalable formulation of vitamin D compound is administered directly to the respiratory tissues of the host such that the compound contacts the respiratory tissue epithelial cells of the host.
  • the respiratory tissue epithelial cells include bronchial epithelial cells, lung epithelial cells, and combinations of lung and bronchial epithelial cells.
  • Vitamin D compounds useful in the methods of the present disclosure include, but are not limited to, inactive vitamins D2 and D3 (e.g., ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ), collectively referred to as "calciferol”); vitamin D2 and D3 prohormones (e.g., 25-hydroxyvitamin D 2 (250HD 2 ) and 25-hydroxyvitamin D 3 (250HD 3 ), collectively “calcidiol”); active vitamin D2 and D3 (e.g., 1 ,25-dihydroxyvitamin D 2 (1 ,25(OH) 2 ) and 1 ,25-dihydroxyvitamin D 3 (1 ,25(OH) 2 D 3 ), collectively “calcitriol”); metabolites of these compounds and combinations of the above.
  • vitamin D compounds may also include less common vitamin D compounds such as Vitamin D1 , Vitamin D4, as well as synthetic versions of the above mentioned Vitamin D compounds.
  • the D compound administered is an inactive form of a vitamin D compound (e.g., ergocalciferol and/or cholecalciferol) and is converted to an active vitamin D compound (e.g., calcitriol, such as, 1 ,25-dihydroxyvitamin D 2 (1 ,25(OH) 2 ) and/or 1 ,25- dihydroxy vitamin D 3 (1 ,25(OH) 2 D 3 )) by lung epithelial cells.
  • a vitamin D compound e.g., ergocalciferol and/or cholecalciferol
  • an active vitamin D compound e.g., calcitriol, such as, 1 ,25-dihydroxyvitamin D 2 (1 ,25(OH) 2
  • lung epithelial cells e.g., calcitriol, such as, 1 ,25-dihydroxyvitamin D 2 (1 ,25(OH) 2
  • calcitriol such as, 1 ,25-dihydroxyvitamin D 2 (1
  • the vitamin D compound is effective to increase the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory tissue epithelial cells of the host.
  • CFTR membrane localized cystic fibrosis conductance regulator
  • the vitamin D compound can be effective to upregulate Keratin 18 (Krt18), Keratin 8 (Krt8), or both, in the respiratory tissue epithelial cells of the host.
  • upregulation of Krt 18 and/or Krt8 may increase membrane localized CFTR by stabilizing the CFTR.
  • the vitamin D compound can be effective to downregulate another protein called activator of Hsp90 ATPase-1 (Aha1) in the respiratory tissue epithelial cells of the host. Downregulation of Aha1 may increase membrane localized CFTR since downregulation of Aha1 rescues misfolded CFTR.
  • administration of the vitamin D compound is effective to decrease activity of the epithelial sodium channel (ENaC) in human bronchial epithelial cells in culture, which helps prevent formation of a dehydrated airway surface layer (ASL) lining of the respiratory tract that can occur due to overactive ENaC.
  • ENaC epithelial sodium channel
  • ASL dehydrated airway surface layer
  • Dehydration, and thus thinning, of the ASL results in many respiratory symptoms in CF patients as well as in other respiratory disorders, such as chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the combined activity of increasing CFTR and decreasing ENaC appear to reduce dehydration of the ASL.
  • the examples demonstrate that administration of a vitamin D compound to the respiratory tissue epithelial cells interrupts pathways that cause dehydration of the ASL responsible respiratory symptoms of subjects, providing a viable treatment for patients with such symptoms.
  • Methods of the present disclosure therefore also include increasing the amount of membrane localized cystic fibrosis conductance regulator (CFTR) on respiratory epithelial tissues in a host with cystic fibrosis.
  • Methods of the present disclosure also include decreasing ENaC activity in a host with cystic fibrosis as well as both increasing the amount of membrane localized CFTR on respiratory tissue cells and decreasing ENaC activity.
  • such methods include administering directly to the respiratory tissue of the host an effective amount of a composition comprising a vitamin D compound, such that the vitamin D compound is effective to increase the amount of membrane localized CFTR, decrease ENaC activity, or both.
  • this method is useful to treat a patient with a respiratory disorder, such as, but not limited to, CF, COPD, and other disorders associated with decreased CFTR activity, increased ENaC activity, or both.
  • the amount of membrane localized CFTR in the host with cystic fibrosis is greater after treatment with CFTR than the amount of membrane localized CFTR in the same host prior to treatment with the vitamin D compound. In embodiments, the amount of membrane localized CFTR in the host with cystic fibrosis is greater than a reference amount of membrane localized CFTR in hosts having cystic fibrosis who have not been treated with the vitamin D compound.
  • a reference amount refers to a reference standard for comparison that is calculated based on an average of amounts of membrane localized CFTR from a certain number of patients with CF. In embodiments, the reference amount may be based on patients meeting similar criteria as the patient being treated, such as age, weight, time since diagnosis, severity of symptoms, type of mutation, etc.
  • the present disclosure also includes compositions for use in the methods of the present disclosure described above.
  • vitamin D compositions are known
  • the present disclosure provides embodiments of aerosolized and aerosolizable formulations including the vitamin D compounds described above.
  • An embodiment of a composition of the present disclosure includes an aerosolized formulation including a vitamin D compound in the form of cholecalciferol (D 3 ) and an pharmaceutically acceptable carrier, wherein the composition is adapted for aerosol delivery by a nebulizer, personal inhaler, or other respiratory airway delivery device,
  • ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited.
  • a concentration range of "about 0.1 % to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt% to about 5 wt%, but also include individual concentrations (e.g., 1 %, 2%, 3%, and 4%) and the sub-ranges (e.g. , 0.5%, 1 .1 %, 2.2%, 3.3%, and 4.4%) within the indicated range.
  • the term “about” can include traditional rounding according to significant figures of the numerical value.
  • the phrase “about 'x' to y” includes “about 'x' to about 'y” ⁇
  • the present example describes the effect of 1 ,25(OH) 2 D 3 on CFTR in vitro and the conversion of vitamin D 3 to active 1 ,25(OH) 2 D 3 in lung epithelial cells.
  • HBE cells Human bronchial epithelial (HBE) cells were from two sources. Normal HBE cells (NHBE) were purchased from Lonza (Walkersville, MD) and grown in bronchial epithelial growth medium (BEGM) from the same company. CF HBE cells were obtained from lungs explanted during transplantation under IRB-approved protocols and were cultured at an air liquid interface (ALI) until well differentiated using well described protocols [24], which is hereby incorporated by reference herein). UNCN3T (non-CF) and UNCCF1 T (CF) cells were provided by University of North Carolina, and have been described previously [25]. BEAS-2B cells were obtained from the American Type Culture Collections (Rockville, MD) and grown in BEGM medium.
  • HEK293 cells were a generous gift University of Florida and were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and penicillin/streptomycin (Thermo Scientific, Rockford, IL). All cells were grown at 37°C in 5% C0 2 . Submerged cells were grown in 12-well plates and cells grown at an ALI were cultured in Transwell® inserts (Fisher Scientific, Pittsburgh, PA).
  • DMEM Dulbecco's Modified Eagle Medium
  • fetal bovine serum Thermo Scientific, Rockford, IL
  • All cells were grown at 37°C in 5% C0 2 .
  • Submerged cells were grown in 12-well plates and cells grown at an ALI were cultured in Transwell® inserts (Fisher Scientific, Pittsburgh, PA).
  • RNA isolation RNA isolation, RT-PCR, and PCR
  • cDNA was amplified using iProof HF Master (Bio-Rad) and fragments were visualized on a 2% agarose gel. Bands were cut out and sent to UF Interdisciplinary Center for Biotechnology Research for Sanger sequencing to confirm identity of the bands, ⁇ -2 - macroglobulin (B2M) was used as the reference gene and primers for both RT-PCR and PCR are listed in Table 1 and were designed and purchased from Integrated DNA
  • Proteins were transferred using the iBIot (Thermo Fisher) transfer apparatus to nitrocellulose membranes.
  • Membranes were blocked in 5% milk in Tris-buffered saline with Tween 20 (TBS-T) and incubated with either anti-Cyp2R1 (Abeam Inc. , Boston, MA), anti-Cyp27A1 EPR7529 (Abeam), anti-Cyp27B1 H-90 (Santa Cruz Biotechnology) or anti-p-actin BA3R (Thermo Fisher) overnight and bands were visualized by chemiluminescence. Densiometric analysis of the bands was performed using ImageJ software.
  • CFTR For intracellular staining of CFTR, cells were permeabilized after fixation with 0.5% TWEEN 20 (Sigma) in PBS. Cells were then blocked in 1 % BSA and the same steps as above were followed. Fluorescence was detected by either confocal microscopy using the Leica TCS-SP5 or flow cytometry using the FACS Calibur cytometer (BD Biosciences, San Jose, CA) . Confocal data was analyzed using LAS AF Lite Software (Leica, Buffalo Grove, IL) and flow cytometry data was analyzed with FCS Express 4 (De Novo Software, Glendale, CA) .
  • CFTR mRNA levels were quantified. All primary patient and UNCCF1 T cells are positive for the F508del mutation. RNA was harvested, and RT-qPCR was performed. Significant increases in CFTR mRNA levels were observed in all cultures at 6 hr. (FIG. 1). In five of the six samples, maximum upregulation was achieved by 6 hours. In the other two samples, CFTR expression was greatest after 24 hours.
  • UNCCF1 T cells were treated with 10 nM 1 ,25(OH) 2 D 3 for 24 hours, fixed, permeabilized, and stained for total CFTR protein.
  • Flow cytometry revealed a second population of cells with a greater fluorescence compared to the EtOH control, which suggests that there was an overall increase in total protein with 1 ,25(OH) 2 D 3 treatment (FIG. 2).
  • the F508del mutation leads to an improperly folded CFTR, and subsequent degradation of the protein prior to reaching the membrane. Therefore, surface expression of CFTR was evaluated by confocal microscopy.
  • UNCCF1 cells were treated with 1 ,25(OH) 2 D 3 for 4 and 24 hours and then cells were permeabilized and stained for both extracellular and intracellular CFTR protein using immunofluorescence. Intracellular protein was detected in EtOH-treated cells, which is expected because F508del mutants are capable of CFTR protein translation, and the protein reaches the cell surface. After both 4 and 24 hours, there is an increase in total fluorescence and therefore total protein, which is consistent with the flow cytometry data (FIG. 3).
  • Bronchial epithelial cells are known to convert 250HD 3 to 1 ,25(OH) 2 D 3 due to the expression of the 1 -alpha hydroxylase Cyp27B1 in these cells [26].
  • both 250HD 3 and 1 ,25(OH) 2 D 3 are not useful clinically due to their dietary short half-life and negative effects on the kidneys, respectively [15-17]. Therefore, it was determined if bronchial epithelial cells could convert the dietary vitamin D 3 to 250HD 3 and ultimately 1 ,25(OH) 2 D 3 .
  • the presence of the two most significant 25-hydroxylases, Cyp27A1 and Cyp2R1 was determined in primary non-CF donors and cystic fibrosis patients (FIG. 4A) .
  • Cyp2R1 and Cyp27A1 expression was detected by PCR and confirmed by DNA sequencing. A similar pattern of expression in BEAS-2B cells was also observed (not shown). Expression of Cyp2R1 and Cyp27A1 protein was also confirmed by western blot of BEAS-2B whole cell lysate. Alongside BEAS-2B cells, kidney HEK293 cell lysates were also probed for both 25- hydroxylases as well as Cyp27B1 . However, very low to undetectable levels of Cyp27A1 and Cyp2R1 were found in the HEK cell line, especially compared to the BEAS-2B cell line.
  • Cyp27B1 was expressed in both HEK293 and BEAS-2B cells, although substantially higher in the kidney cells, which was expected due to the kidney's previously established major role in vitamin D metabolism (FIG. 4B).
  • NHBE cells were treated with vitamin D at increasing concentrations, and 250HD 3 levels were quantified in the supernatant by ELISA.
  • the result shown in FIG. 4C demonstrates a dose-dependent increase in 250HD 3 levels, indicating that the vitamin D 3 was converted to 250HD 3 by the cultured cells.
  • CF- derived epithelial cells were capable of converting vitamin D 3 to 250HD 3 . A very similar conversion compared to NHBE's was found and it was confirmed that disease does not impact bronchial epithelial cells ability to metabolize vitamin D locally.
  • Cyp24A1 was upregulated 31 fold after 6 hours and 6 fold at 24 hours in NHBE cells. Total mRNA was isolated after 6 and 24 hours, and CYP24A1 gene expression was quantified by QRT-PCR. Cyp24A1 was upregulated 62 fold at 6 hours and increased to 132 fold relative to the control in UNCN3 cells.
  • Cyp24A1 was upregulated only 12.5 fold and was the least amount of the three cell lines at 6 hours, but by 24 hours, Cyp24A1 expression was the greatest of the cell lines at 300 fold.
  • the relative expression of LL-37 was also quantified, which is known to be upregulated after 1 ,25(OH) 2 D 3 treatment in bronchial epithelial cells.
  • LL-37 was upregulated in all three cell lines, with BEAS-2B cells expressing the greatest levels after 24 hours of vitamin D 3 treatment (data not shown).
  • the vitamin D 3 was applied in a small volume (1 ⁇ ) at 10 ⁇ on the apical surface of ALI cultures for 6 hours in order to demonstrate the ability to deliver high concentrations to the airway surface that could be rapidly converted to the active form.
  • CFTR was quantified as above relative to 0.1 % ethanol treated cultures. Induction in all cases was significant at p ⁇ 0.001 .
  • RNAseq was carried out on mRNA from NHBE cells treated with 1 ,25(OH) 2 D 3 for 24 hours. Briefly, UNC-CF1 cells were incubated with either ethanol or 1 ,25(OH) 2 D 3 , and mRNA levels of Krt18 (FIG. 6, right bar) and Aha1 (FIG. 6, left bar) were quantified by QRT-PCR. Optimal times are shown for each gene: for Krt18 optimal time of induction was 4 hours, and for Aha1 optimal time for reduction was 24 hours.
  • Keratin 18 is an intermediate filament protein which stabilizes CFTR and increases its surface protein expression [27].
  • the RNAseq data indicated a 2-fold induction of Krt18 mRNA in these cells. This was confirmed in UNC-CF1 cells, with an optimal induction seen at 6 hours (FIG. 6, right-hand bar). A similar level of induction of Krt8 was observed, which dimerizes with Krt18 (data not shown).
  • Aha1 is a heat shock protein 90 (Hsp90) co-chaperone. Downregulation of Aha 1 rescues misfolded CFTR in CF cells [28]. The RNAseq showed a 2.4-fold
  • CFTR mRNA, protein, and surface expression were upregulated significantly in bronchial epithelial cells. These changes were detected through qPCR, flow cytometry and confocal microscopy and were observed through a wide variety of cultured and primary lung epithelial cells from both CF and non-CF donors. As we were able to observe an increase in CFTR protein levels as early as 6 hours, it is believed that vitamin D may simultaneously be acting on multiple pathways: the standard transcriptional pathway, and one that regulates CFTR transport. While all cultures demonstrated induction of CFTR mRNA, there was variability in both the extent of induction and the timing. This can be seen both in cell lines and patient samples. This may be due to variability in other aspects of gene regulation between the cells, which are known to exist in vitamin D-mediated gene regulation [29].
  • the standard mechanism of transcriptional activation would involve the entry of 1 ,25(OH) 2 D 3 into the cell, followed by the VDR-mediated activation of the transcription of CFTR, which would lead to an overall increase in CFTR protein expression.
  • VDR-mediated activation of the transcription of CFTR When analyzing the promoter region for transcription factor binding sites using the JASPAR database, several weak putative VDREs were detected. Considering that the CFTR mRNA increased approximately two fold in most cell types tested, a weak VDRE may account for these low levels. However, it would likely not account for the increase in surface expression seen so early. Vitamin D is also known to have numerous intracellular nongenomic roles in addition to transcriptional activation.
  • vitamin D could also be affecting CFTR transport post-transcriptionally.
  • proteins that are common to both CFTR and the vitamin D pathway For example, vitamin D has been reported to interact with the heat shock proteins and other intracellular chaperones, such as Bag-1 , which help to correct CFTR folding and surface expression [33].
  • a second protein common to both pathways is ERp57, which has been found to be complexed with F508del CFTR but also serves as the vitamin D receptor found in the plasma membrane [34-36]. Therefore, vitamin D may be binding to these molecules to allow for correct CFTR folding.
  • 1 ,25(OH) 2 D 3 upregulates CFTR, and could be potentially useful therapeutically.
  • 1 ,25(OH) 2 D 3 while effective in vitro, has its limitations as a therapy. It only has a half-life of several hours and has the undesirable side effect of hypercalcemia. Currently, it is only approved to raise calcium levels in patients undergoing long-term dialysis. The precursor, 250HD 3 has a longer half-life in the serum, but like 1 ,25(OH) 2 D 3 , is only approved for increasing serum calcium due to the same negative side effects.
  • Vitamin D 3 is the form most commonly taken as an oral supplement and is the most stable, but it must be converted to 250HD 3 in the liver and 1 ,25(OH) 2 D 3 in the kidney to be activated. It is known that BEC can convert 250HD 3 to 1 ,25(OH) 2 D 3 [26].
  • BEC can convert 250HD 3 to 1 ,25(OH) 2 D 3 [26].
  • these epithelial cells not only express the hydroxylases to convert vitamin D 3 to 250HD 3 , but treatment with vitamin D 3 also activates 1 ,25(OH) 2 D 3 dependent genes. More importantly, vitamin D 3 treatment also exhibited the same increase in CFTR mRNA as the 1 ,25(OH) 2 D 3 treatment.
  • HEK cells were unable to activate these genes after vitamin D 3 treatment nor was any substantial protein expression of 25-hydroxylases detected. This was not surprising due to the fact that HEK cells are kidney cells and are primarily focused on the second conversion.
  • mice were intranasally treated with EtOH , or 1 ⁇ 1 ,25(OH) 2 D 3 for 6 hours, sacrificed, and the nasal epithelia, trachea, and lungs were harvested.
  • RT-qPCR confirmed Cyp24A1 mRNA upregulation in both the nasal epithelia (data not shown) and trachea in 1 ,25(OH) 2 D 3 -treated mice.
  • CFTR mRNA expression was also upregulated in the 1 ,25(OH) 2 D 3 treated mice (FIG. 7) .
  • results are shown in the graphs of FIGS. 8A and 8B, which demonstrate that both genes (CYP24A1 and CFTR) are induced by intranasal delivery of vitamin D 3 and 1 ,25D 3 .
  • Results show fold increase in mRNA levels of CYP24A1 (8A) or CFTR (8B) relative to control. Results are shown as means +/- SEM and differences are significant with p ⁇ 0.05 by t-test.
  • 24 hours after the third injection mice were sacrificed, and lung and nasal epithelium were excised. Total mRNA was isolated, and CYP24A1 mRNA was quantified by QRT-PCR, relative to ⁇ - actin.
  • the results shown in FIG. 9 demonstrate that this vitamin D-regulated gene is induced by systemic treatment with the active form of vitamin D in vivo, although the kinetics appears to vary between the tissues.
  • CF patients may be chronically vitamin D deficient because they are unable to absorb fat-soluble vitamins. Whatever is successfully absorbed must undergo two hydroxylation steps in two different organs before the activated form can be delivered to the lung. Even with supplementation, it is unlikely that sufficient levels of 1 ,25(OH) 2 D 3 will reach the airway to induce CFTR expression. Topical administration of vitamin D 3 , which would be converted locally, would therefore have an improved effect on CFTR as well as the additional benefit of the activation of antimicrobial and anti-inflammatory genes.
  • vitamin D-mediated induction of CFTR may only lead to a small effect on CFTR function, this may be sufficient to have effects on CF symptoms.
  • Additional studies on the topical delivery of vitamin D directly to the airways in in aerosol formulations may be able to obtain higher efficiency and delivery in greater amounts to deeper respiratory tissues, such as lung tissues.
  • this effect could be combined with recently developed CFTR modifiers. To date, only two drugs are approved by the FDA to target CFTR in cystic fibrosis but each must be taken orally and both have displayed Iimitations clinically.
  • Ivacaftor corrects faulty chloride ion transport and only can treat patients who have a CFTR mutation that allows CFTR to reach the surface, which amounts to just 4% of the CF population [38].
  • Lumacaftor is designed to treat patients with the more prevalent F508del mutation by correcting faulty CFTR processing, but only produces small effects on lung function and lower exacerbation rates [39-40]. Because the results here demonstrate that vitamin D results in increased CFTR surface localization in CF bronchial epithelial cells, it is believed that vitamin D can be utilized as a therapy for CF or as an adjunctive therapy to improve the efficacy of the approved drugs.
  • vitamin D is an appealing therapeutic agent for the treatment of CF due to its anti-inflammatory properties and ability to induce antimicrobial activity, but the results in this study suggest another, more direct role for vitamin D by increasing CFTR levels.
  • vitamin D targets CFTR directly and is FDA approved, but is also inexpensive. Vitamin D is well-tolerated at high levels, which would minimize the concern of overdosing patients. Not only are the results presented promising on their own, but additional studies involving synergy of vitamin D and the FDA approved drugs holds great potential.
  • BECs Primary human bronchial epithelial cells
  • ALI air liquate interface
  • ALI BEC well-differentiated cultures were then treated with 0.1 % ethanol vehicle or 10 nM 1 ,25(OH) 2 D 3 for 24 hours, and ion transport was quantified in Ussing chambers. This analysis was repeated in triplicate cultures from 18 different donors (8 non-CF, 9 AF508/AF508 CF and one G542X/G542X CF).
  • the ethanol control only or 1 ,25(OH) 2 D 3 was added to a media of human bronchial epithelial cells grown at an air-liquid interface. 24 hours later, the cells were subjected to analysis in Ussing chambers, a device that enables assessment of ion channel activity. While a significant difference was not observed in short circuit current (/sc) stimulated by forskolin, which measures CFTR activity, a consistent 33% reduction in amiloride-sensitive /sc was observed, which is indicative of ENaC activity.
  • FIG. 10A illustrates a tracing of short circuit current across the epithelial cells as a function of time, with vertical arrows indicating when certain chemicals were added to the Ussing chamber.
  • FIG. 10B illustrates the mean relative ENaC activity (measured as function of amiloride- sensitive short circuit current) in triplicate wells from CF and non-CF donors, indicating that the effect of vitamin D treatment is consistent in both CF and non-CF respiratory epithelial cells.
  • the results illustrate that the cultures treated with 1 ,25(OH) 2 D 3 had lower amiloride- sensitive short circuit current than cultures just receiving an equal concentration of the ethanol vehicle.
  • G542X/G542X donor the mean of triplicates is shown). The mean reduction over all 18 patients was to 67.33+/-3.78% of the control value.
  • the airway surface layer is a thin layer of salt, water, and protein that lines the respiratory tract and facilitates innate immunity in the lung.
  • the ASL is made of two layers, one that is directly adjacent to the epithelial cells, which is called the periciliary layer (PCL), and another, called the mucus layer, which lies on top of the PCL. Maintaining a hydrated ASL provides a low-viscosity environment for cilia to beat effectively and to propel mucus, pathogens, and particles toward the mouth. Furthermore, a dehydrated ASL accelerates the development of mucus plugs, which can obstruct air flow and serve as focal points for bacterial colonization. ASL hydration is controlled by the transepithelial movement of ions and water.
  • anions are mostly secreted by CFTR, and Na + is absorbed by the epithelial sodium channel (ENaC).
  • ENaC epithelial sodium channel
  • cystic fibrosis where CFTR is mutated and has disrupted or diminished function, the balance between anion secretion and Na + absorption is altered. Absence of functioning CFTR leads to reduced anion secretion and triggers hyperactive ENaC that excessively absorbs Na + , which together leads to dehydrated ASL.
  • Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis, J Cyst Fibros, 10 (201 1 ) 428-434.
  • Vitamin D receptor is not required for the rapid actions of 1 ,25-dihydroxyvitamin D3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts, J Cell Biochem, 88 (2003) 794-801.
  • VDR Vitamin D receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés et des compositions comprenant des composés de vitamine D pour le traitement de troubles respiratoires, tels que la fibrose kystique, y compris des symptômes associés à la fibrose kystique ou à d'autres troubles respiratoires.
PCT/US2017/019351 2016-02-25 2017-02-24 Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires Ceased WO2017147420A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299651P 2016-02-25 2016-02-25
US62/299,651 2016-02-25

Publications (1)

Publication Number Publication Date
WO2017147420A1 true WO2017147420A1 (fr) 2017-08-31

Family

ID=59685654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/019351 Ceased WO2017147420A1 (fr) 2016-02-25 2017-02-24 Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires

Country Status (1)

Country Link
WO (1) WO2017147420A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800020185A1 (it) * 2018-12-19 2020-06-19 Davide Fiumi Formulazioni contenenti vitamina d3 in film edibile per il trattamento di pazienti affetti da malassorbimento
EP4132484A1 (fr) * 2020-04-10 2023-02-15 Galenus G.H. AG Composition comprenant du resvératrol

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053827A1 (fr) * 1997-05-30 1998-12-03 Ramot University Authority For Applied Research And Industrial Development Ltd. Traitement de l'osteoporose
WO2003028674A2 (fr) * 2001-10-02 2003-04-10 Cedars-Sinai Medical Center Procede pour stimuler la repousse des cheveux par l'administration des analogues de la vitamine d
WO2005082375A2 (fr) * 2004-03-01 2005-09-09 Bioxell Spa Methodes permettant de traiter la cystite interstitielle et composes et compositions connexes
WO2007117661A2 (fr) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd, Microparticules médicamenteuses
US7812150B2 (en) * 2006-05-19 2010-10-12 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
US20110059917A1 (en) * 2009-08-14 2011-03-10 Joaquin Jimenez Vitamin d3 and analogs thereof for treating alopecia
US8058295B2 (en) * 2002-09-30 2011-11-15 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US20140017691A1 (en) * 2011-02-04 2014-01-16 Medizinische Hochschule Hannover Novel method for the production of differentiated respiratory epithelial cells
WO2015168574A1 (fr) * 2014-05-02 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs des canaux sodiques épithéliaux (enac) pour traiter le psoriasis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053827A1 (fr) * 1997-05-30 1998-12-03 Ramot University Authority For Applied Research And Industrial Development Ltd. Traitement de l'osteoporose
WO2003028674A2 (fr) * 2001-10-02 2003-04-10 Cedars-Sinai Medical Center Procede pour stimuler la repousse des cheveux par l'administration des analogues de la vitamine d
US8058295B2 (en) * 2002-09-30 2011-11-15 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2005082375A2 (fr) * 2004-03-01 2005-09-09 Bioxell Spa Methodes permettant de traiter la cystite interstitielle et composes et compositions connexes
WO2007117661A2 (fr) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd, Microparticules médicamenteuses
US7812150B2 (en) * 2006-05-19 2010-10-12 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
US20110059917A1 (en) * 2009-08-14 2011-03-10 Joaquin Jimenez Vitamin d3 and analogs thereof for treating alopecia
US20140017691A1 (en) * 2011-02-04 2014-01-16 Medizinische Hochschule Hannover Novel method for the production of differentiated respiratory epithelial cells
WO2015168574A1 (fr) * 2014-05-02 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs des canaux sodiques épithéliaux (enac) pour traiter le psoriasis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIKLE, DD: "Vitamin D metabolism, mechanism of action, and clinical applications", CHEM BIOL., vol. 21, no. 3, 20 March 2014 (2014-03-20), pages 319 - 329, XP055413097 *
HANSDOTTIR, S ET AL.: "Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense", JOURNAL OF IMMUNOLOGY, vol. 181, no. 10, 15 November 2008 (2008-11-15), pages 7090 - 7099, XP055412949 *
HERON, LL ET AL.: "Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone", JOURNAL OF CYSTIC FIBROSIS, vol. 9, no. 1, 2010, pages 69 - 72, XP026834326 *
JACKSON, SE: "Hsp90: Structure and Function", TOPICS IN CURRENT CHEMISTRY, vol. 328, September 2012 (2012-09-01), pages 155 - 240 *
MOSKOWITZ, SM ET AL.: "Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders", GENETICS IN MEDICINE, vol. 10, no. 12, 1 December 2008 (2008-12-01), pages 851 - 868, XP055413096 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800020185A1 (it) * 2018-12-19 2020-06-19 Davide Fiumi Formulazioni contenenti vitamina d3 in film edibile per il trattamento di pazienti affetti da malassorbimento
EP4132484A1 (fr) * 2020-04-10 2023-02-15 Galenus G.H. AG Composition comprenant du resvératrol

Similar Documents

Publication Publication Date Title
TWI252756B (en) Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed
TW474823B (en) Powder formulations containing, as a diluent, D-melezitose (Α-D-melezitose), β-D-glucopyranoside, O-Α-D-glucopyranosyl-1,3-β-D-fructofuranosyl (β-D-melezitose) or isomelezitose
EP2719391B1 (fr) Procédé d'administration d'un surfactant pulmonaire
JP2019116503A (ja) 肥満細胞安定剤による全身性障害の治療
JP2010503731A (ja) 肺サーファクタント製剤および粘液クリアランスの促進方法
EP3331522A1 (fr) Méthodes de traitement de troubles liés aux mastocytes par des stabilisateurs de mastocytes
JP2023113852A (ja) 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物
WO2015014209A1 (fr) Compositions pharmaceutiques de pyruvate pour la stabilité osmotique et effet de désintoxication de celles-ci chez des êtres humains en bonne santé et des patients atteints d'affections pulmonaires
HK1219046A1 (zh) 包括肺表面活性物质和类固醇的治疗组合
WO2017147420A1 (fr) Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires
CN113164425A (zh) 用于治疗囊性纤维化的氨基酸组合物和方法
WO2009032955A1 (fr) Compositions d'inhalation de dhea
WO2018111903A1 (fr) Préparations salines de peptides splunc1
CN107137518A (zh) 一种止喘灵雾化吸入用溶液制剂及其制备方法
EP2421520B1 (fr) Albumine et/ou mannitol pour le traitement de la polypose nasale
JP7378425B2 (ja) 肺サーファクタントおよびｂｐｄの予防のためのステロイドを含む治療的組合せ
US12357651B2 (en) Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections
US20220168304A1 (en) Methods for treating cystic fibrosis
CN115400201A (zh) Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途
HK1165724B (en) Albumin and/or mannitol for the treatment of nasal polyposis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17757301

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17757301

Country of ref document: EP

Kind code of ref document: A1